Digest Network Come funziona
Network
/
Società
F.
Non verificato

F. Hoffmann-La Roche Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaPubblicità/Marketing/Media/Comunicazione

149 comunicati stampa

Guarda tutti i comunicati
24/07/2026
Farmaceutica
Annunci Economici
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
22/07/2026
Farmaceutica
Annunci Economici
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
14/07/2026
Farmaceutica
Annunci Economici
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
13/07/2026
Farmaceutica
Annunci Economici
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/07/2026
Farmaceutica
Annunci Economici
Roche receives CE Mark for blood test to identify tuberculosis infection
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
06/07/2026
Farmaceutica
Annunci Economici
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
01/07/2026
Farmaceutica
Annunci Economici
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
29/06/2026
Farmaceutica
Annunci Economici
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
28/06/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
17/06/2026
Farmaceutica
Annunci Economici
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0